Clinical trials: Oral Disorder
Macular Edema
Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema
This is a proof of mechanism trial to explore the effect of BI 1026706 on the central retinal thickness and to evaluate safety and tolerability of BI 1026706 administered orally for 12 weeks in patients with mild vision…
- Trial name
- NCT02732951
- Testing
- BI 1026706
- Where
- 35 sites in Belgium, France and 6 more
- Volunteers
- 105 people
- Sponsor
- Boehringer Ingelheim
Bone and Joint Infection
Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)
The problem of interest is that doctors are looking for new antibiotic treatments for bone and joint infections. Treatment for bone and joint infection is not standardized, which allows a wide range of antibiotic therapy to…
- Trial name
- NCT03009045
- Testing
- Tedizolid
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
This was a 10-week, placebo-controlled, randomized study to investigate the effect of injectable IL-1B antagonist, Canakinumab , in participants with impaired glucose tolerance or Type 2 Diabetes Mellitus (T2DM) already treated…
- Trial name
- NCT01068860
- Testing
- Canakinumab 150 mg
- Where
- 52 sites in United States, Australia and 5 more
- Volunteers
- 246 people
- Sponsor
- Novartis
Alzheimer's Disease
ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.
- Trial name
- NCT00934050
- Testing
- ELND005 (scyllo-inositol)
- Where
- 38 sites in United States, Canada
- Volunteers
- 103 people
- Sponsor
- OPKO Health, Inc.
Cerebral Palsy
Managing Post-operative Pain in Children With Cerebral Palsy Using a Pain Pump
The purpose of this study is to determine which pain management strategy continuous analgesic pump or orally-should be used in the management of children with cerebral palsy.
- Trial name
- NCT00884650
- Testing
- oral analgesic, intravenous analgesic per pump
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Colorado, Denver
Asthma
Trial of One Versus Two Doses of Dexamethasone for Pediatric Asthma Exacerbation
Comparing one versus two doses of oral dexamethasone for the treatment of asthma in the pediatric emergency department.
- Trial name
- R2D2 (NCT02725008)
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Geoffrey W Jara-Almonte
Focal Infection, Dental
AUGMENTIN™ in Dental Infections
In clinical practice, amoxicillin + clavulanic acid is widely used in the treatment of odontogenic infection. Therefore, this study is designed to generate data to support its use by demonstrating efficacy, safety and…
- Trial name
- AUGDENT (NCT02141217)
- Testing
- Amoxicillin/clavulanate, Clindamycin
- Where
- 15 sites in Malaysia, Philippines and 2 more
- Volunteers
- 472 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder
The purpose of this study is to assess the long-term safety, tolerability and efficacy of oral OPC-34712 as adjunctive therapy in the treatment of adult patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01447576
- Testing
- ADT, OPC-34712
- Where
- 32 sites in United States
- Volunteers
- 1,036 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Amyotrophic Lateral Sclerosis (ALS)
Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)
This is a Phase 3, international, multicenter, open-label, long-term extension study. The primary objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral…
- Trial name
- NCT04577404
- Testing
- MT-1186
- Where
- 44 sites in United States, Canada and 4 more
- Volunteers
- 124 people
- Sponsor
- Shionogi
Cirrhosis, Portal Hypertension
Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
This is a multicenter, randomized, double-blind, placebo-controlled trial involving subjects with NASH cirrhosis and severe portal hypertension (defined as HVPG ≥12 mmHg as determined by the central reader assigned to this…
- Conditions
- Cirrhosis, Portal Hypertension, Non-alcoholic Steatohepatitis
- Trial name
- ENCORE-PH (NCT02960204)
- Testing
- Emricasan
- Where
- 37 sites in United States, Germany and 1 more
- Volunteers
- 263 people
- Sponsor
- Histogen
Diabetes Mellitus, Type 2
Response To Oral Agents in Diabetes (ROAD)- Pilot Study
This proposal is to fund a pilot study to assess feasibility and refine methodology for an intended large Scotland wide study on Response to Oral Agents in Diabetes (ROAD).
- Trial name
- ROAD (NCT00780715)
- Testing
- Gliclazide MR, Sitagliptin, Pioglitazone
- Where
- United Kingdom
- Volunteers
- 29 people
- Sponsor
- University of Dundee
Major Cutaneous Abscess, Cellulitis
A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study
Characterization of the safety profile of TR-701 Free Acid (FA) in patients with major cutaneous abscess or cellulitis/erysipelas.
- Conditions
- Major Cutaneous Abscess, Cellulitis, Erysipelas
- Trial name
- NCT01519778
- Testing
- TR701 FA
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Rheumatoid Arthritis
Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis
This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with rheumatoid arthritis and high A3AR expression at baseline will relieve signs and symptoms of the disease.
- Trial name
- NCT01034306
- Testing
- CF101
- Where
- 5 sites in Bulgaria, Israel
- Volunteers
- 79 people
- Sponsor
- Can-Fite BioPharma
Diabetes Mellitus, Type 2
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
The objective of the study is to investigate the efficacy, safety and tolerability of linagliptin 5 mg qd compared to placebo given for 24 weeks in inadequately controlled T2DM patients on empagliflozin 10 mg or 25 mg and maximum…
- Trial name
- NCT01778049
- Testing
- BI 10773, BI 10773 / BI 1356
- Where
- 114 sites in United States, Argentina and 9 more
- Volunteers
- 708 people
- Sponsor
- Boehringer Ingelheim
Primary Ciliary Dyskinesia
Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia
To evaluate the safety and efficacy of treatment with VX-371 with and without ivacaftor, and the effect of VX-371 with and without ivacaftor on quality of life (QOL) in subjects with primary ciliary dyskinesia (PCD).
- Trial name
- CLEAN-PCD (NCT02871778)
- Testing
- VX-371, Hypertonic Saline, VX-371 + HS
- Where
- 34 sites in United States, Canada and 6 more
- Volunteers
- 123 people
- Sponsor
- Parion Sciences
Urea Cycle Disorder
Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)
This is a randomized, controlled, open-label parallel arm study to assess the safety, tolerability, pharmacokinetics and ammonia control, of RAVICTI® as compared to Sodium phenylbutyrate (NaPBA) in urea cycle disorder subjects…
- Trial name
- NCT03335488
- Testing
- RAVICTI, NaPBA
- Where
- 11 sites in United States, Italy and 2 more
- Volunteers
- 16 people
- Sponsor
- Amgen
Acne
Apremilast in the Treatment of Moderate to Severe Acne
Acne is a chronic inflammatory disease of the pilosebaceous unit that affects 80-90% of the population, especially teenagers, although adult acne is a significant problem for 3-6 % of adult men and 5-12% of adult women.
- Trial name
- NCT01074502
- Testing
- apremilast
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Glucose Intolerance, Aortic Stiffness
Healthy Aging Through Functional Food
The purpose of this study is to determine whether dietary inducers of glyoxalase 1 are effective in improving metabolic and vascular health.
- Conditions
- Glucose Intolerance, Aortic Stiffness, Vasodilation
- Trial name
- HATFF (NCT02095873)
- Testing
- Glyoxalase 1 (Glo1) inducer
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Warwick
COVID-19
Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19
The purpose of this trial is to assess the safety, tolerability and treatment effect of the orally administered Caspase-1 inhibitor, belnacasan, for the treatment of patients with mild to moderate COVID-19 and to generate proof…
- Trial name
- NCT05164120
- Testing
- Belnacasan
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- MedStar Health
Schizophrenia
An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia
The purpose of the study is to explore the maintained efficacy, tolerability, and safety of flexibly dosed paliperidone extended-release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional…
- Trial name
- NCT00757705
- Testing
- Paliperidone ER
- Volunteers
- 299 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.